Canadian Large Cap Leaders Split Corp. Receives Approval for Normal Course Issuer Bid
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Ninepoint Partners LP ('Ninepoint'), on behalf of Canadian Large Cap Leaders Split Corp. (the 'Company') (TSX: NPS/NPS.PR.A), announced today that the Toronto Stock Exchange (the 'TSX') has accepted its notice of intention to make a normal course issuer bid (the 'NCIB') to purchase its class A shares ('Class A Shares') and preferred shares ('Preferred Shares') through the facilities of the TSX and alternative trading systems in Canada. The NCIB will commence on June 9, 2025 and terminate on June 8, 2026.
Pursuant to the NCIB, the Company proposes to purchase, from time to time, up to 176,492 Class A Shares and 176,492 Preferred Shares of the Company, representing 10% of the public float of 1,764,915 Class A Shares and 1,764,915 Preferred Shares. As of June 4th, 2025, there were 1,764,915 Class A Shares and 1,764,915 Preferred Shares issued and outstanding. The Company will not purchase, in any given 30-day period, in the aggregate, more than 35,298 Class A Shares or more than 35,298 Preferred Shares, being 2% of the issued and outstanding Class A Shares and Preferred Shares as of June 4th, 2025.
Under Ninepoint Partners prior NCIB, which commenced on May 28, 2024 and ended on May 27, 2025, Ninepoint Partners obtained approval to purchase up to a total of 209,947 Common Shares, reflecting a security split that took effect on Feb 4, 2025, and 182,563 Preferred Shares, of which 49,450, on the post-split basis, Common Shares, and 43,000 Preferred Shares were purchased through the facilities of the TSX at a weighted-average price of approximately $10.39, on the post-split basis, per Common Share, and $10.45 for Preferred Shares.
Ninepoint, the manager of the Company, believes that such purchases are in the best interests of the Company and are a desirable use of its funds. All purchases will be made through the facilities noted above and in accordance with the rules and policies of the TSX. All Class A Shares or Preferred Shares purchased by the Company pursuant to the NCIB will be cancelled.
About Ninepoint Partners LPBased in Toronto, Ninepoint Partners LP is one of Canada's leading alternative investment management firms overseeing approximately $7 billion in assets under management and institutional contracts. Committed to helping investors explore innovative investment solutions that have the potential to enhance returns and manage portfolio risk, Ninepoint offers a diverse set of alternative strategies spanning Equities, Fixed Income, Alternative Income, Real Assets, F/X and Digital Assets.
For more information on Ninepoint, please visit www.ninepoint.com or for inquiries regarding the Offering, please contact us at (416) 943-6707 or (866) 299-9906 or invest@ninepoint.com.
Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions 'expects', 'intends', 'anticipates', 'will' and similar expressions to the extent that they relate to the Company. The forward-looking statements are not historical facts but reflect Ninepoint's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although Ninepoint believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. Neither the Company nor Ninepoint undertake any obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law.Sign in to access your portfolio

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
11 hours ago
- Business Wire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ('Edgewise' or 'the Company') (NASDAQ: EWTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Edgewise reported data from the clinical trials on its drug candidate sevasemten on June 26, 2025. The Company claimed the results were positive but also disclosed that the FDA had "deemed the CANYON data alone insufficient for an accelerated approval." Based on this news, shared of Edgewise fell by 8.86% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


Business Wire
16 hours ago
- Business Wire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altimmune, Inc. ('Altimmune' or 'the Company') (NASDAQ: ALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Altimmune announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)," on June 26, 2025. Although the Company characterized the results as 'positive,' it added that 'the effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant)." Based on this news, shares of Altimmune fell by 52.18% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


Business Wire
16 hours ago
- Business Wire
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. ('Unicycive' or 'the Company') (NASDAQ: UNCY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Unicycive announced on June 30, 2025, that the FDA 'has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis." The Company added that "After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection." Based on this news, shares of Unicycive fell by 29.85% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.